Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Spectrum Pharmaceuticals announced that the target enrollment has been reached for the Phase 2 study of belinostat in Carcinoma of Unknown Primary (CUP). The study is an open-label, randomized, controlled trial in which patients with previously untreated CUP, were randomized into one of two treatment arms: Belinostat + carboplatin and paclitaxel (BelCaP), or carboplatin and paclitaxel (CaP). The primary objective of the CUP study is to provide an estimate of the treatment effect of BelCaP compared to CaP in terms of progression-free survival, response rate, and overall survival in patients with CUP.
Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effect is thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis (programmed cell death), inhibition of angiogenesis, induction of differentiation, and the resensitization of cells that have become resistant to anticancer agents such as platinums, taxanes and topoisomerase II inhibitors.
For more information call (949) 788-6700 or visit www.sppirx.com.
http://www.sppirx.com/
.
